secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-06-06T23:59:59+00:00
Accession:  0001193125-23-161593
Event type: other
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Taysha grants performance-based options to CEO (666.5K), President (477.2K), CFO (268K)
--------------------------------------------------------------------------------

- CEO Sean Nolan receives 666,500 options; President Sukumar Nagendran 477,150; CFO Kamran Alam 267,975.
- Awards tied to clinical, regulatory, and corporate milestones by Dec 31, 2023; vest over 3 years.
- Board revised director compensation: initial equity grant set at 43,800 shares; annual at 36,200 shares.
- Options under 2020 Stock Incentive Plan; intended to strengthen pay-for-performance alignment.
- No departure reported; grants are one-time performance-based equity incentives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523161593/0001193125-23-161593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523161593/d480804d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-161593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer